Sun Pharmaceutical Industries Limited has announced the launch of a comprehensive Shareholder Satisfaction Survey aimed at gathering valuable feedback on the services provided by its Registrar and Transfer Agent (RTA). The initiative reflects the company's commitment to maintaining strong relationships with shareholders and continuously improving service delivery.

Survey Details and Timeline

The survey will focus on services rendered by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's RTA. The feedback collection process has been structured with specific parameters to ensure meaningful and relevant responses.

Participation Criteria and Objectives

Participation in the survey is limited to shareholders who have actively availed RTA services during the specified nine-month period from April 1, 2025, to December 31, 2025. This targeted approach ensures that feedback comes from shareholders with direct experience of the services being evaluated.

The company has emphasized that the survey's primary objective is to obtain constructive and experience-based feedback. This approach will enable the company to:

• Improve efficiency in RTA service delivery
• Enhance service quality across all touchpoints
• Increase responsiveness to shareholder needs
• Strengthen overall shareholder services and engagement

Implementation and Communication

Sun Pharmaceutical Industries Limited will send specific communications via email to eligible shareholders, ensuring direct outreach to those who can provide relevant feedback. The company has encouraged all eligible shareholders to actively participate in the survey, highlighting the vital role their feedback will play in service enhancement.

The survey represents part of the company's periodic review process, demonstrating its commitment to continuous improvement in shareholder services. The feedback collected will be used to evaluate current service standards and identify areas for enhancement in the RTA's service delivery model.

Sun Pharmaceutical Industries has achieved a significant regulatory milestone with the US Food and Drug Administration's acceptance of its supplemental biologics license application for Ilumya® (tildrakizumab-asnm). The FDA has accepted the sBLA for review to expand the therapeutic scope of this biologic therapy to include treatment of adults diagnosed with active psoriatic arthritis, with a regulatory action date expected by October 29, 2026.

Regulatory Application Details

The FDA acceptance marks an important step in the regulatory process for expanding Ilumya's approved indications. This sBLA specifically covers the treatment of adults with active psoriatic arthritis, building on the established clinical experience of Ilumya as an IL-23 inhibitor for moderate-to-severe plaque psoriasis.

Clinical Trial Foundation

The sBLA submission is based on results from the INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies evaluating the efficacy and safety of Ilumya in adult patients with active psoriatic arthritis. Both studies are 52-week global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials assessing tildrakizumab 100 mg in this patient population. Top-line findings from these studies were reported in July 2025.

Market Position and Patient Impact

If approved, this would represent a significant expansion for Ilumya, which received its original US FDA approval in 2018 for moderate-to-severe plaque psoriasis. The drug has since received additional approvals for scalp and nail plaque psoriasis in April 2024 and December 2025, respectively. Ilumya has supported nearly 140,000 patients worldwide and has received marketing authorization from over 55 worldwide health authorities.

Therapeutic Significance

Psoriatic arthritis affects roughly 1 in 3 people living with psoriasis, with as many as 2.4 million Americans living with the condition. The potential approval would position Ilumya as the only HCP-administered IL-23 biologic for active psoriatic arthritis treatment. Rick Ascroft, CEO of Sun Pharma North America, emphasized the company's ambition for Ilumya to become a differentiated first-choice advanced systemic treatment for this condition.